By Angélique Bouchard
America’s New Drug Doctrine
In 2025, the Trump administration is radically reshaping U.S. federal drug policy, marked by a stark contrast: a relentless security offensive against fentanyl – viewed as an existential imported threat – and a pragmatic easing on medical cannabis, despite internal Republican resistance…
As the opioid crisis, which at its peak caused over 100,000 annual overdose deaths, sees significant declines in overdoses, this dual approach embodies an “America First” vision: muscular repression against foreign threats, flexibility on popular domestic issues. It highlights the priorities of Trump’s second term: national security, border control, and responding to societal demands, while navigating ideological fractures within the GOP.
The opioid crisis remains one of America’s greatest public health challenges, having peaked at over 100,000 overdose deaths per year. In 2025, under President Donald Trump’s second administration, federal policy adopts a reinforced security approach, centering on fentanyl as a national threat, while maintaining some treatment programs amid controversial budget cuts.
À lire aussi : DÉCRYPTAGE – La Croatie, le réarmement comme choix politique
Crackdown on Fentanyl: Labeled a “Weapon of Mass Destruction”
On December 15, 2025, President Trump signed an executive order designating illicit fentanyl as a “weapon of mass destruction” (WMD). This unprecedented classification for a narcotic equates the synthetic opioid to a chemical weapon, justifying expanded use of national security tools.
The order directs Attorney General Pam Bondi to intensify criminal prosecutions with aggravated penalties for traffickers. It also targets financial assets linked to production and distribution, primarily through Mexican cartels and Chinese chemical precursors.
Earlier, in July 2025, Trump signed the HALT Fentanyl Act, permanently classifying fentanyl-related substances (FRS) in Schedule I, closing loopholes exploited by cartels through minor molecular tweaks.
The administration justifies these measures by the crisis’s scale: in 2024, around 80,000 overdose deaths, nearly 48,000 from synthetic opioids like fentanyl. Despite a 27% drop in overdoses in 2024 – the sharpest in decades – Trump emphasizes a “law and order” approach, blaming porous borders and foreign networks. Offenses involving FRS trigger the same quantity thresholds and penalties as fentanyl analogs (e.g., 100 grams or more mandates a minimum 10-year sentence).
On December 3, 2025, the Trump administration unveiled Fentanyl Free America, a comprehensive initiative combining enforcement and public awareness to reduce both supply and demand for fentanyl.
In an exclusive Fox News interview, DEA Administrator Terrance “Terry” Cole highlighted progress from military operations in the Caribbean Sea and increased pressure on cartel supply chains.
Fentanyl Free America rests on two pillars:
• Intensified enforcement: Targeted operations against Mexican cartels (Sinaloa and CJNG), labeled “narco-terrorists” by the DEA.
• Public awareness: Education in schools from a young age, resources for parents, and community mobilization (leaders, educators, physicians).
Cole described traffickers as “foreign terrorists” deliberately targeting children via social media. At DEA headquarters, a memorial wall displays thousands of victim photos, symbolizing the agency’s commitment.
Claimed results are encouraging:
• In 2025, only 29% of analyzed fentanyl pills contained a potentially lethal dose (down from 76% in 2023).
• Fentanyl powder purity dropped to 10.3% (from 19.5%).
• By December 1, 2025, the DEA seized over 45 million pills and more than 9,000 pounds (about 4,082 kg) of powder – equivalent to 347 million potentially deadly doses.
These seizures align with a decline in synthetic opioid deaths to levels not seen since April 2020.
Cole praised U.S. military strikes on suspected vessels in the Caribbean, ordered by Defense Secretary Pete Hegseth. These operations raised cocaine prices (often laced with fentanyl) upon arrival in the Dominican Republic and Puerto Rico. The controversial lethal strikes targeted presumed trafficking boats.
Cole also publicly accused the Hells Angels of controlling “a good portion” of drug trafficking from Canada across the northern border into the U.S. This highlights a growing threat via the less-monitored northern frontier. Canadian Hells Angels, especially in British Columbia, collaborate with the Sinaloa cartel for fentanyl production and distribution, sourcing precursors through Asian networks while handling local distribution and cross-border transport.
Canada has become a synthetic fentanyl production hub, with dismantled superlabs producing millions of counterfeit pills. The Hells Angels leverage mobility and networks to move drugs into the U.S. via rural routes (e.g., Montana).
À lire aussi : DÉCRYPTAGE – L’Estonie fortifie sa frontière
Trump Signs Executive Order to Reschedule Cannabis to Schedule III, Defying GOP Critics
On December 18, 2025, President Trump signed an executive order directing federal agencies to expedite rescheduling cannabis from Schedule I to Schedule III. This marks a major shift in U.S. drug policy, recognizing legitimate medical use for the first time while maintaining federal prohibition on recreational use.
At the White House ceremony, Trump stated: “This in no way legalizes cannabis or endorses recreational use.” He emphasized facilitating medical research into benefits for chronic pain, incurable diseases, and other conditions, responding to patients, veterans, and seniors.
The order instructs Attorney General Pam Bondi to “take all necessary steps to finalize rescheduling expeditiously.” The process, initiated under Biden but stalled, followed HHS recommendations citing recognized medical potential and moderate abuse risk.
Currently in Schedule I – alongside heroin and LSD, deemed to have no accepted medical use and high abuse potential – cannabis would move to Schedule III, with drugs like ketamine, anabolic steroids, or codeine Tylenol.
Rescheduling would:
• Ease regulatory barriers for scientific studies.
• Allow legal cannabis businesses to deduct ordinary expenses (ending IRS 280E penalty).
• Potentially pave the way for FDA-approved cannabis-derived pharmaceuticals.
The White House stressed no recreational legalization, aiming to “enhance research on medical cannabis and CBD to better inform patients and physicians.”
Despite industry support and public opinion (nearly 70% of Americans favor some legalization per recent polls), the move faced sharp GOP opposition.
Hours before signing, 26 House Republicans – led by Pete Sessions (Texas) and Andy Harris (Maryland, Freedom Caucus chair) – urged Trump to abandon it, calling cannabis a “harmful drug worsening America’s addiction crisis.” They warned it would send the “wrong message” to children, aid cartels (including China-linked ones), and endanger roads via impaired driving.
A similar letter from 22 Republican senators echoed health and economic risks.
Trump dismissed critics, calling it a “common-sense approach” based on science and patient needs.
The reform fits a landscape where 38 states have legalized medical cannabis and 24 recreational adult use. It completes a long-stalled process and could enable Medicare coverage for some CBD products.
Final rescheduling still requires DEA procedures, potentially taking months. Observers say it could boost Trump’s support among young and swing-state voters while deepening GOP tensions.
À lire aussi : ANALYSE – Matthew et Hunter : Quand deux rochers révèlent le naufrage stratégique français
Reauthorization of Key Programs Amid Budget Cuts
In December 2025, Trump signed reauthorization of the SUPPORT for Patients and Communities Act (originally 2018), extending prevention, treatment, and recovery programs for substance use disorders to 2030, including grants for recovery centers and opioid initiatives.
However, the administration proposes massive cuts to federal mental health and addiction funding, criticized by experts. Reductions target SAMHSA, naloxone distributions, and medication-assisted treatments (e.g., methadone, buprenorphine).
These cuts, part of broader fiscal reforms, aim to reduce spending but risk limiting care access, especially in rural and vulnerable areas.
Opioid Settlement Funds: A Key Resource for States
Independent of federal policy, states and localities receive billions from settlements with pharmaceutical companies (Purdue Pharma, Johnson & Johnson, distributors like CVS/Walgreens). In 2025, Purdue and the Sackler family paid an additional $7.4 billion.
Totaling over $50 billion nationally, these funds prioritize prevention, treatment, and harm reduction. States allocate via advisory councils, with observed overdose reductions linked to investments (about 2.5% drop per per-capita dollar spent).
Overdoses have declined since 2023 (30% drop for fentanyl), thanks to treatments, naloxone, and local efforts. But experts fear a rebound from federal cuts and overemphasis on repression over public health.
Trump’s approach contrasts with harm-reduction proposals, criticized by the administration as enabling use.
À lire aussi : RENSEIGNEMENT – La ligne de front sans frontières : Le MI6 de Blaise Metreweli à l’ère de la compétition permanente
*
* *
A Geopolitical and Political Pivot
Trump’s 2025 drug reforms are more than public health policy: they embed in a hybrid geopolitical war. By labeling fentanyl a “weapon of mass destruction” and escalating military strikes and sanctions against Mexican cartels and Chinese precursors, Washington elevates narcotrafficking to a strategic threat, justifying border militarization and heightened pressure on Beijing and Mexico City.
This bolsters the “America First” axis: implicit accusations of China as a malign actor, tensions with Canada over the northern border, and disruption of Caribbean routes. Politically, the contrast is telling: uncompromising repression on opioids to rally the conservative anti-immigration base, pragmatism on cannabis to capture moderate and young voters in battleground states.
Ultimately, Trump maneuvers GOP divisions while projecting a strong-leader image against “foreign invasions,” turning the drug crisis into a lever of American power on the global stage.
The Diplomat Media will continue tracking these developments and their geopolitical repercussions.
#Trump2025, #FentanylCrisis, #DrugWar, #AmericaFirst, #OpioidEpidemic, #HALTFentanyl, #FentanylWMD, #USDrugPolicy, #BorderSecurity, #MexicanCartels, #ChinaPrecursors, #DEA, #WarOnDrugs, #CannabisPolicy, #MedicalCannabis, #CannabisRescheduling, #ScheduleIII, #GOPDivisions, #PublicHealth, #NationalSecurity, #NarcoTerrorism, #SyntheticOpioids, #DrugGeopolitics, #TrumpDoctrine, #LawAndOrder, #WhiteHousePolicy, #DrugEnforcement, #CartelViolence, #CannabisReform, #OpioidDeaths, #USPolitics2025, #FederalPolicy, #DEAOperations, #DrugTrafficking, #NorthAmericanSecurity, #ChinaUSRelations, #USCanadaBorder, #CartelNetworks, #DrugSecurity
Diplômée de la Business School de La Rochelle (Excelia – Bachelor Communication et Stratégies Digitales) et du CELSA – Sorbonne Université, Angélique Bouchard, 25 ans, est titulaire d’un Master 2 de recherche, spécialisation « Géopolitique des médias ». Elle est journaliste indépendante et travaille pour de nombreux médias. Elle est en charge des grands entretiens pour Le Dialogue.